Price Alert

Equillium Inc. (EQ)

NASDAQ: EQ · Real-Time Price · USD

1.91

0.16 (9.14%)

At close: Sep 05, 2025, 3:59 PM

1.94

1.57%

After-hours: Sep 05, 2025, 07:56 PM EDT

9.14% (1D)

Bid	1.94
Market Cap	68.22M
Revenue (ttm)	16.55M
Net Income (ttm)	-20.19M
EPS (ttm)	-0.57
PE Ratio (ttm)	-3.35
Forward PE	-6.23
Analyst	Hold

Ask	1.97
Volume	7,279,671
Avg. Volume (20D)	8,435,150
Open	1.73
Previous Close	1.75
Day's Range	1.73 - 2.35
52-Week Range	0.27 - 2.35
Beta	1.57

About EQ

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol EQ

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for EQ stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

+78.88%

Equillium shares are trading higher after the comp... Unlock content with Pro Subscription

1 month ago

+81.59%

Shares of energy stocks are trading lower as oil prices fall on demand concerns amid US tariffs.

News

2 days ago · businesswire.com

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).

1 week ago · businesswire.com

Equillium to Participate in the Cantor Global Healthcare Conference 2025

LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium to Participate in the Cantor Global Healthcare Conference 2025.

3 weeks ago · businesswire.com

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium, Inc. (“Equillium” or the “Company”) (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inf...

1 month ago · businesswire.com

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

LA JOLLA, Calif.--(BUSINESS WIRE)-- #Bitcoin--Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced ...